Reversing Diabetes: The Power of Diet, Lifestyle, and Scientific Breakthroughs

In recent years, the concepts of diabetes remission and reversal have become central to discussions about managing and treating type 2 diabetes. While these terms are often used interchangeably, they have distinct meanings. Understanding these differences is crucial for grasping the potential of achieving long-term control—and even the possible eradication—of diabetes.

This article will explain the differences between remission and reversal, the scientific basis for each, and how our evidence-based approach helps individuals accomplish what many believe is impossible: true diabetes reversal.

Defining Diabetes Remission

Diabetes remission refers to achieving an A1c level below 6.5% for at least three months without the need for diabetes medications, achieved through sustained diet and lifestyle changes.

Remission, therefore, marks a significant milestone in the management of diabetes, demonstrating that blood sugar levels have been brought under control. However, it's important to note that remission does not mean the disease is cured. The potential for relapse exists if lifestyle changes are not maintained because the underlying causes of diabetes, such as insulin resistance, may still persist.

The American Diabetes Association defines remission in three stages:

1. Partial remission: Blood glucose levels are lower than the diabetic range but higher than normal without medications for at least one year.
2. Complete remission: Blood glucose levels are within the normal range without medications for at least one year.
3. Prolonged remission: Complete remission sustained for at least five years.

However, remission is reversible if the root causes of diabetes, such as poor diet or lack of exercise, resurface.

What is Diabetes Reversal?

Diabetes reversal, by contrast, goes beyond remission. It implies that the disease process has been halted and potentially reversed to the extent that an individual no longer meets the criteria for diabetes, even after more extended periods. In simple terms, diabetes reversal means normal sugar metabolism is restored, insulin sensitivity is reestablished, and, in some cases, pancreatic beta cells may regenerate.

Achieving diabetes reversal requires addressing the root causes of the disease, not just controlling blood sugar. By tackling insulin resistance, reducing fat buildup in the liver and pancreas, and promoting beta cell health, diabetes can be reversed, leading to a long-term or permanent restoration of metabolic health.

The Root Causes of Type 2 Diabetes

The primary factor behind type 2 diabetes is insulin resistance, where the body's cells become less responsive to insulin. As a result, the pancreas compensates by producing more insulin, but over time, it may fail to keep up, leading to elevated blood sugar levels and diabetes. Other factors include fat accumulation in the liver and pancreas, chronic inflammation, and mitochondrial dysfunction, all of which contribute to the decline in insulin sensitivity and the loss of beta cells that produce insulin.

Diet and Lifestyle: The Path to Reversing Diabetes

One of the most effective methods for reversing type 2 diabetes is through targeted diet and lifestyle interventions. Studies show that a whole-food, plant-based diet combined with physical activity can significantly improve insulin sensitivity, reduce inflammation, and promote fat loss. For example, the landmark DIRECT trial showed that low-calorie diets led to diabetes remission in 46% of participants after one year. This was achieved primarily by reducing fat in the liver and pancreas, which helped restore normal insulin production and sugar metabolism.

Moreover, emerging evidence suggests that certain dietary approaches, like low-fat, high-carb, plant-based diets, are particularly effective at restoring insulin sensitivity by reducing intramyocellular fat (fat inside muscle cells), a key driver of insulin resistance.

The Science Behind Diabetes Reversal

The idea of diabetes reversal isn't speculative; it's supported by scientific studies.

One of the most prominent researchers in this field is Dr. Roy Taylor from Newcastle University. His research demonstrated that a low-calorie diet could reduce liver and pancreatic fat, thus restoring insulin sensitivity and leading to remission. Dr. Taylor’s work found that reducing liver fat leads to improvements in glucose regulation within just a week, with fat loss in the pancreas following closely behind, restoring insulin production.

Studies like these support the idea that diet and lifestyle interventions can reverse the disease process, not just manage symptoms.

The Role of Beta Cell Regeneration in Reversing Diabetes

Another exciting area of research is the potential for regenerating pancreatic beta cells, which are responsible for producing insulin. In people with long-term diabetes, these cells often become dysfunctional or die off. Research led by Dr. Valter Longo at the University of Southern California on fasting-mimicking diets (FMD) offers hope. Fasting-mimicking diets have been shown to regenerate beta cells in animal models and restore normal insulin production.

In mice, FMD cycles reversed diabetes symptoms, and while human trials are still in their early stages, preliminary results suggest improved insulin sensitivity and metabolic health.

Once a Diabetic, Always a Diabetic?

Despite the mounting evidence, there remains skepticism within the medical community regarding diabetes reversal, partly due to the long-standing belief that beta cell damage is irreversible. This view is increasingly challenged by new research in regenerative medicine and metabolic rewiring. For many individuals with type 2 diabetes, especially those who are newly diagnosed or still producing insulin, reversing insulin resistance can lead to full metabolic recovery.

The prevailing belief that diabetes is an irreversible condition has persisted for many years. However, recent scientific advancements are challenging this notion and offering hope.

While it's true that beta cell damage can occur in advanced stages of diabetes, reversing insulin resistance is often the key to achieving remission or even reversal. By addressing the underlying causes of insulin resistance, such as fat accumulation in the liver and pancreas, individuals can restore their body's ability to regulate glucose effectively.

The myth that diabetes is a one-way street stems from the misconception that carbohydrates are the primary culprit. While excessive carbohydrate intake can contribute to high blood sugar levels in those with insulin resistance, it's not the root cause of the disease.

The true culprit is insulin resistance itself, which can be exacerbated by factors such as obesity, sedentary lifestyle, and diet. By addressing these underlying factors, individuals can significantly improve their metabolic health and potentially reverse the disease process.

It's important to note that not everyone with diabetes will be able to fully reverse the condition. The extent of beta cell damage and insulin resistance can influence the individual's ability to achieve complete reversal. However, even those who are unable to fully reverse diabetes can still significantly improve their health and well-being through lifestyle modifications and targeted interventions.

While the term "once a diabetic, always a diabetic" may have been prevalent in the past, it's no longer a definitive statement. With the right approach, individuals with type 2 diabetes may achieve remission or even reversal, restoring their metabolic health and improving their quality of life.

The Role of Insulin Resistance in Diabetes Reversal

Insulin resistance is central to type 2 diabetes and, by extension, its reversal. Reversing insulin resistance is key for most people with type 2 diabetes, especially those who haven't experienced significant beta cell loss. Reducing intramyocellular fat and improving mitochondrial function are vital for restoring insulin sensitivity. Achieving this can be done through scientifically proven lifestyle modifications that reduce fat inside cells and allow insulin to work efficiently again.

Why Blood Sugar Control Alone is Not Enough

While blood sugar control is essential, it’s only part of the picture. True diabetes reversal requires the restoration of the body's natural ability to regulate glucose under all conditions, not just in a fasting state. For example, tolerating high-carbohydrate meals without experiencing spikes in blood sugar is a more reliable indicator of reversal than merely having normal fasting blood glucose.

The Importance of Personalized Approaches

No one-size-fits-all approach exists for reversing diabetes. Each individual’s health status, level of insulin resistance, and beta cell function must be considered when designing a diabetes reversal strategy. For example, some people may benefit more from plant-based diets, while others might see faster results with intermittent fasting or more rigorous physical activity.

The Future of Diabetes Reversal

The future of diabetes care is increasingly focused on remission and reversal rather than mere management. With ongoing research into beta cell regeneration, insulin sensitivity, and new dietary strategies, we are on the cusp of a new era in diabetes treatment. For many people, particularly those recently diagnosed or with less beta cell damage, remission or reversal may be within reach.

While remission is an essential milestone, true diabetes reversal is the ultimate goal. By addressing the root causes of the disease—such as insulin resistance, pancreatic and liver function, and mitochondrial and gut health—through scientifically backed lifestyle changes, many individuals can reverse the disease process, restoring healthy blood sugar regulation and achieving long-term metabolic health.

If you or a loved one is struggling with diabetes, know that putting the root causes of diabetes into reverse possible with the right approach.

Our program is designed to guide you through scientifically validated steps that address the root causes of diabetes, helping you achieve sustainable health and wellness.

Contact us today to talk with us about what diabetes remission or reversal could look like for you. 

References: 

• Abad M, Mosteiro L, Pantoja C, Canamero M, Rayon T, Ors I, Grana O, Megias D, Dominguez O, Martinez D, et al. Reprogramming in vivo produces teratomas and iPS cells with totipotency features. Nature. 2013;502:340–345. [PubMed] [Google Scholar]
• Angelidi AM, Filippaios A, Mantzoros CS. Severe insulin resistance syndromes. J Clin Invest. 2021 Feb 15;131(4):e142245. doi: 10.1172/JCI142245. PMID: 33586681; PMCID: PMC7880309.
• Arakawa K, Ishihara T, Oku A, Nawano M, Ueta K, Kitamura K, Matsumoto M, Saito A. Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095. British journal of pharmacology. 2001;132:578–586. [PMC free article] [PubMed] [Google Scholar]
• Arnes L, Hill JT, Gross S, Magnuson MA, Sussel L. Ghrelin expression in the mouse pancreas defines a unique multipotent progenitor population. PloS one. 2012;7:e52026. [PMC free article] [PubMed] [Google Scholar]
• Baeyens L, Lemper M, Leuckx G, De Groef S, Bonfanti P, Stange G, Shemer R, Nord C, Scheel DW, Pan FC, et al. Transient cytokine treatment induces acinar cell reprogramming and regenerates functional beta cell mass in diabetic mice. Nature biotechnology. 2014;32:76–83. [PMC free article] [PubMed] [Google Scholar] Retracted
• Barnosky AR, Hoddy KK, Unterman TG, Varady KA. Intermittent fasting vs daily calorie restriction for type 2 diabetes prevention: a review of human findings. Translational research : the journal of laboratory and clinical medicine. 2014;164:302–311. [PubMed] [Google Scholar]
• Blum B, Roose AN, Barrandon O, Maehr R, Arvanites AC, Davidow LS, Davis JC, Peterson QP, Rubin LL, Melton DA. Reversal of beta cell de-differentiation by a small molecule inhibitor of the TGFbeta pathway. eLife. 2014;3:e02809. [PMC free article] [PubMed] [Google Scholar]
• Brandhorst S, Choi IY, Wei M, Cheng CW, Sedrakyan S, Navarrete G, Dubeau L, Yap LP, Park R, Vinciguerra M, et al. A Periodic Diet that Mimics Fasting Promotes Multi-System Regeneration, Enhanced Cognitive Performance, and Healthspan. Cell Metab. 2015;22:86–99. [PMC free article] [PubMed] [Google Scholar]
• Brereton MF, Iberl M, Shimomura K, Zhang Q, Adriaenssens AE, Proks P, Spiliotis II, Dace W, Mattis KK, Ramracheya R, et al. Reversible changes in pancreatic islet structure and function produced by elevated blood glucose. Nature communications. 2014;5:4639. [PMC free article] [PubMed] [Google Scholar]
• Burhans MS, Hagman DK, Kuzma JN, Schmidt KA, Kratz M. Contribution of Adipose Tissue Inflammation to the Development of Type 2 Diabetes Mellitus. Compr Physiol. 2018 Dec 13;9(1):1-58. doi: 10.1002/cphy.c170040. PMID: 30549014; PMCID: PMC6557583.
• Cheng CW, Adams GB, Perin L, Wei M, Zhou X, Lam BS, Da Sacco S, Mirisola M, Quinn DI, Dorff TB, et al. Prolonged fasting reduces IGF-1/PKA to promote hematopoietic-stem-cell-based regeneration and reverse immunosuppression. Cell stem cell. 2014;14:810–823. [PMC free article] [PubMed] [Google Scholar]
• Cheng CW, Villani V, Buono R, Wei M, Kumar S, Yilmaz OH, Cohen P, Sneddon JB, Perin L, Longo VD. Fasting-Mimicking Diet Promotes Ngn3-Driven β-Cell Regeneration to Reverse Diabetes. Cell. 2017 Feb 23;168(5):775-788.e12. doi: 10.1016/j.cell.2017.01.040. PMID: 28235195; PMCID: PMC5357144.
• Chera S, Baronnier D, Ghila L, Cigliola V, Jensen JN, Gu G, Furuyama K, Thorel F, Gribble FM, Reimann F, et al. Diabetes recovery by age-dependent conversion of pancreatic delta-cells into insulin producers. Nature. 2014;514:503–507. [PMC free article] [PubMed] [Google Scholar]
• Cnop M, Welsh N, Jonas JC, Jorns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes. 2005;54(Suppl 2):S97–107. [PubMed] [Google Scholar]
• Cohen DE, Melton D. Turning straw into gold: directing cell fate for regenerative medicine. Nature reviews Genetics. 2011;12:243–252. [PubMed] [Google Scholar]
• Cook JR, Matsumoto M, Banks AS, Kitamura T, Tsuchiya K, Accili D. A Mutant Allele Encoding DNA-Binding-Deficient Foxo1 Differentially Regulates Hepatic Glucose and Lipid Metabolism. Diabetes 2015 [PMC free article] [PubMed] [Google Scholar]
• Dirice E, Kahraman S, Jiang W, El Ouaamari A, De Jesus DF, Teo AK, Hu J, Kawamori D, Gaglia JL, Mathis D, et al. Soluble factors secreted by T cells promote beta-cell proliferation. Diabetes. 2014;63:188–202. [PMC free article] [PubMed] [Google Scholar]
• Dor Y, Glaser B. beta-cell dedifferentiation and type 2 diabetes. The New England journal of medicine. 2013;368:572–573. [PubMed] [Google Scholar]
• Fazakerley DJ, Chaudhuri R, Yang P, Maghzal GJ, Thomas KC, Krycer JR, Humphrey SJ, Parker BL, Fisher-Wellman KH, Meoli CC, Hoffman NJ, Diskin C, Burchfield JG, Cowley MJ, Kaplan W, Modrusan Z, Kolumam G, Yang JY, Chen DL, Samocha-Bonet D, Greenfield JR, Hoehn KL, Stocker R, James DE. Mitochondrial CoQ deficiency is a common driver of mitochondrial oxidants and insulin resistance. Elife. 2018 Feb 6;7:e32111. doi: 10.7554/eLife.32111. PMID: 29402381; PMCID: PMC5800848.
• Fazakerley DJ, Minard AY, Krycer JR, Thomas KC, Stöckli J, Harney DJ, Burchfield JG, Maghzal GJ, Caldwell ST, Hartley RC, Stocker R, Murphy MP, James DE. Mitochondrial oxidative stress causes insulin resistance without disrupting oxidative phosphorylation. J Biol Chem. 2018 May 11;293(19):7315-7328. doi: 10.1074/jbc.RA117.001254. Epub 2018 Mar 29. PMID: 29599292; PMCID: PMC5950018.
• Fiorina P, Shapiro AM, Ricordi C, Secchi A. The clinical impact of islet transplantation. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2008;8:1990–1997. [PubMed] [Google Scholar]
• Gomez DL, O’Driscoll M, Sheets TP, Hruban RH, Oberholzer J, McGarrigle JJ, Shamblott MJ. Neurogenin 3 Expressing Cells in the Human Exocrine Pancreas Have the Capacity for Endocrine Cell Fate. PloS one. 2015;10:e0133862. [PMC free article] [PubMed] [Google Scholar]
• Grunnet LG, Aikin R, Tonnesen MF, Paraskevas S, Blaabjerg L, Storling J, Rosenberg L, Billestrup N, Maysinger D, Mandrup-Poulsen T. Proinflammatory cytokines activate the intrinsic apoptotic pathway in beta-cells. Diabetes. 2009;58:1807–1815. [PMC free article] [PubMed] [Google Scholar]
• Haeusler RA, Hartil K, Vaitheesvaran B, Arrieta-Cruz I, Knight CM, Cook JR, Kammoun HL, Febbraio MA, Gutierrez-Juarez R, Kurland IJ, et al. Integrated control of hepatic lipogenesis versus glucose production requires FoxO transcription factors. Nature communications. 2014;5:5190. [PMC free article] [PubMed] [Google Scholar]
• Heinrich C, Spagnoli FM, Berninger B. In vivo reprogramming for tissue repair. Nature cell biology. 2015;17:204–211. [PubMed] [Google Scholar]
• Hsu FL, Huang CF, Chen YW, Yen YP, Wu CT, Uang BJ, Yang RS, Liu SH. Antidiabetic effects of pterosin A, a small-molecular-weight natural product, on diabetic mouse models. Diabetes. 2013;62:628–638. [PMC free article] [PubMed] [Google Scholar]
• Johnson JD, Han Z, Otani K, Ye H, Zhang Y, Wu H, Horikawa Y, Misler S, Bell GI, Polonsky KS. RyR2 and calpain-10 delineate a novel apoptosis pathway in pancreatic islets. J Biol Chem. 2004;279:24794–24802. [PubMed] [Google Scholar]
• Kim-Muller JY, Zhao S, Srivastava S, Mugabo Y, Noh HL, Kim YR, Madiraju SR, Ferrante AW, Skolnik EY, Prentki M, et al. Metabolic inflexibility impairs insulin secretion and results in MODY-like diabetes in triple FoxO-deficient mice. Cell Metab. 2014;20:593–602. [PMC free article] [PubMed] [Google Scholar]
• Kroon E, Martinson LA, Kadoya K, Bang AG, Kelly OG, Eliazer S, Young H, Richardson M, Smart NG, Cunningham J, et al. Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nature biotechnology. 2008;26:443–452. [PubMed] [Google Scholar]
• Laviano A, Rossi Fanelli F. Toxicity in chemotherapy--when less is more. The New England journal of medicine. 366:2319–2320. [PubMed] [Google Scholar]
• Lebastchi J, Herold KC. Immunologic and metabolic biomarkers of beta-cell destruction in the diagnosis of type 1 diabetes. Cold Spring Harbor perspectives in medicine. 2012;2:a007708. [PMC free article] [PubMed] [Google Scholar]
• Lee SH, Park SY, Choi CS. Insulin Resistance: From Mechanisms to Therapeutic Strategies. Diabetes Metab J. 2022 Jan;46(1):15-37. doi: 10.4093/dmj.2021.0280. Epub 2021 Dec 30. PMID: 34965646; PMCID: PMC8831809.
• Li DS, Yuan YH, Tu HJ, Liang QL, Dai LJ. A protocol for islet isolation from mouse pancreas. Nature protocols. 2009;4:1649–1652. [PubMed] [Google Scholar]
• Li M, Chi X, Wang Y, Setrerrahmane S, Xie W, Xu H. Trends in insulin resistance: insights into mechanisms and therapeutic strategy. Signal Transduct Target Ther. 2022 Jul 6;7(1):216. doi: 10.1038/s41392-022-01073-0. PMID: 35794109; PMCID: PMC9259665.
• Madisen L, Zwingman TA, Sunkin SM, Oh SW, Zariwala HA, Gu H, Ng LL, Palmiter RD, Hawrylycz MJ, Jones AR, et al. A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. Nature neuroscience. 2010;13:133–140. [PMC free article] [PubMed] [Google Scholar]
• Maehr R, Chen S, Snitow M, Ludwig T, Yagasaki L, Goland R, Leibel RL, Melton DA. Generation of pluripotent stem cells from patients with type 1 diabetes. Proceedings of the National Academy of Sciences of the United States of America. 2009;106:15768–15773. [PMC free article] [PubMed] [Google Scholar]
• Matthews DR. Insulin resistance and beta-cell function--a clinical perspective. Diabetes, obesity & metabolism. 2001;3(Suppl 1):S28–33. [PubMed] [Google Scholar]
• Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419. [PubMed] [Google Scholar]
• McKnight KD, Wang P, Kim SK. Deconstructing pancreas development to reconstruct human islets from pluripotent stem cells. Cell stem cell. 2010;6:300–308. [PMC free article] [PubMed] [Google Scholar]
• Meier JJ, Butler AE, Saisho Y, Monchamp T, Galasso R, Bhushan A, Rizza RA, Butler PC. Beta-cell replication is the primary mechanism subserving the postnatal expansion of beta-cell mass in humans. Diabetes. 2008;57:1584–1594. [PMC free article] [PubMed] [Google Scholar]
• Milanesi A, Lee JW, Li Z, Da Sacco S, Villani V, Cervantes V, Perin L, Yu JS. beta-Cell regeneration mediated by human bone marrow mesenchymal stem cells. PloS one. 2012;7:e42177. [PMC free article] [PubMed] [Google Scholar]
• Mu J, Woods J, Zhou YP, Roy RS, Li Z, Zycband E, Feng Y, Zhu L, Li C, Howard AD, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes. 2006;55:1695–1704. [PubMed] [Google Scholar]
• Pagliuca FW, Millman JR, Gurtler M, Segel M, Van Dervort A, Ryu JH, Peterson QP, Greiner D, Melton DA. Generation of functional human pancreatic beta cells in vitro. Cell. 2014;159:428–439. [PMC free article] [PubMed] [Google Scholar]
• Pipeleers D, Keymeulen B, Chatenoud L, Hendrieckx C, Ling Z, Mathieu C, Roep B, Ysebaert D. A view on beta cell transplantation in diabetes. Ann N Y Acad Sci. 2002;958:69–76. [PubMed] [Google Scholar]
• Piran R, Lee SH, Li CR, Charbono A, Bradley LM, Levine F. Pharmacological induction of pancreatic islet cell transdifferentiation: relevance to type I diabetes. Cell death & disease. 2014;5:e1357. [PMC free article] [PubMed] [Google Scholar]
• Rabinovitch A. An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus. Diabetes/metabolism reviews. 1998;14:129–151. [PubMed] [Google Scholar]
• Raffaghello L, Lee C, Safdie FM, Wei M, Madia F, Bianchi G, Longo VD. Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proceedings of the National Academy of Sciences of the United States of America. 2008;105:8215–8220. [PMC free article] [PubMed] [Google Scholar]
• Sneddon JB, Borowiak M, Melton DA. Self-renewal of embryonic-stem-cell-derived progenitors by organ-matched mesenchyme. Nature. 2012;491:765–768. [PMC free article] [PubMed] [Google Scholar]
• Stanger BZ. HNF4A and diabetes: injury before insult? Diabetes. 2008;57:1461–1462. [PubMed] [Google Scholar]
• Talchai C, Xuan S, Lin HV, Sussel L, Accili D. Pancreatic beta cell dedifferentiation as a mechanism of diabetic beta cell failure. Cell. 2012;150:1223–1234. [PMC free article] [PubMed] [Google Scholar]
• Talchai SC, Accili D. Legacy Effect Of Foxo1 In Pancreatic Endocrine Progenitors On Adult beta-cell Mass And Function. Diabetes 2015 [PMC free article] [PubMed] [Google Scholar]
• Teta M, Long SY, Wartschow LM, Rankin MM, Kushner JA. Very slow turnover of beta-cells in aged adult mice. Diabetes. 2005;54:2557–2567. [PubMed] [Google Scholar]
• Tonne JM, Sakuma T, Deeds MC, Munoz-Gomez M, Barry MA, Kudva YC, Ikeda Y. Global gene expression profiling of pancreatic islets in mice during streptozotocin-induced beta-cell damage and pancreatic Glp-1 gene therapy. Dis Model Mech. 6:1236–1245. [PMC free article] [PubMed] [Google Scholar]
• Van de Casteele M, Leuckx G, Baeyens L, Cai Y, Yuchi Y, Coppens V, De Groef S, Eriksson M, Svensson C, Ahlgren U, et al. Neurogenin 3+ cells contribute to beta-cell neogenesis and proliferation in injured adult mouse pancreas. Cell death & disease. 2013;4:e523. [PMC free article] [PubMed] [Google Scholar]
• Villani V, Milanesi A, Sedrakyan S, Da Sacco S, Angelow S, Conconi MT, Di Liddo R, De Filippo R, Perin L. Amniotic fluid stem cells prevent beta-cell injury. Cytotherapy. 2014;16:41–55. [PMC free article] [PubMed] [Google Scholar]
• Wang S, Jensen JN, Seymour PA, Hsu W, Dor Y, Sander M, Magnuson MA, Serup P, Gu G. Sustained Neurog3 expression in hormone-expressing islet cells is required for endocrine maturation and function. Proceedings of the National Academy of Sciences of the United States of America. 2009;106:9715–9720. [PMC free article] [PubMed] [Google Scholar]
• Wang Z, York NW, Nichols CG, Remedi MS. Pancreatic beta Cell Dedifferentiation in Diabetes and Redifferentiation following Insulin Therapy. Cell Metab. 19:872–882. [PMC free article] [PubMed] [Google Scholar]
• Wang Z, York NW, Nichols CG, Remedi MS. Pancreatic beta cell dedifferentiation in diabetes and redifferentiation following insulin therapy. Cell Metab. 2014;19:872–882. [PMC free article] [PubMed] [Google Scholar]
• Weinberg N, Ouziel-Yahalom L, Knoller S, Efrat S, Dor Y. Lineage tracing evidence for in vitro dedifferentiation but rare proliferation of mouse pancreatic beta-cells. Diabetes. 2007;56:1299–1304. [PubMed] [Google Scholar]
• Weir GC, Aguayo-Mazzucato C, Bonner-Weir S. beta-cell dedifferentiation in diabetes is important, but what is it? Islets. 2013;5:233–237. [PMC free article] [PubMed] [Google Scholar]
• Wu KK, Huan Y. Streptozotocin-induced diabetic models in mice and rats. Curr Protoc Pharmacol. 2008;Chapter 5(Unit 5):47. [PubMed] [Google Scholar]
• Xiao X, Chen Z, Shiota C, Prasadan K, Guo P, El-Gohary Y, Paredes J, Welsh C, Wiersch J, Gittes GK. No evidence for beta cell neogenesis in murine adult pancreas. The Journal of clinical investigation. 2013;123:2207–2217. [PMC free article] [PubMed] [Google Scholar]
• Xu J, Du Y, Deng H. Direct lineage reprogramming: strategies, mechanisms, and applications. Cell stem cell. 2015;16:119–134. [PubMed] [Google Scholar]
• Xu X, D’Hoker J, Stange G, Bonne S, De Leu N, Xiao X, Van de Casteele M, Mellitzer G, Ling Z, Pipeleers D, et al. Beta cells can be generated from endogenous progenitors in injured adult mouse pancreas. Cell. 2008;132:197–207. [PubMed] [Google Scholar]
• Yi P, Park JS, Melton DA. Betatrophin: a hormone that controls pancreatic beta cell proliferation. Cell. 2013;153:747–758. [PMC free article] [PubMed] [Google Scholar] Retracted
• Yilmaz OH, Katajisto P, Lamming DW, Gultekin Y, Bauer-Rowe KE, Sengupta S, Birsoy K, Dursun A, Yilmaz VO, Selig M, et al. mTORC1 in the Paneth cell niche couples intestinal stem-cell function to calorie intake. Nature. 2012;486:490–495. [PMC free article] [PubMed] [Google Scholar]
• Yin D, Tao J, Lee DD, Shen J, Hara M, Lopez J, Kuznetsov A, Philipson LH, Chong AS. Recovery of islet beta-cell function in streptozotocin-induced diabetic mice: an indirect role for the spleen. Diabetes. 2006;55:3256–3263. [PubMed] [Google Scholar]
• Zhernakova A, Alizadeh BZ, Eerligh P, Hanifi-Moghaddam P, Schloot NC, Diosdado B, Wijmenga C, Roep BO, Koeleman BP. Genetic variants of RANTES are associated with serum RANTES level and protection for type 1 diabetes. Genes and immunity. 2006;7:544–549. [PubMed] [Google Scholar]
• Zhou M, Konigsberg WH, Hao C, Pan Y, Sun J, Wang X. Bioactivity and mechanisms of flavonoids in decreasing insulin resistance. J Enzyme Inhib Med Chem. 2023 Dec;38(1):2199168. doi: 10.1080/14756366.2023.2199168. PMID: 37036026; PMCID: PMC10088969.
• Zhou Q, Brown J, Kanarek A, Rajagopal J, Melton DA. In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. Nature. 2008;455:627–632. [PMC free article] [PubMed] [Google Scholar]